# Article information:

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma | NEJM
[https://www.nejm.org/doi/10.1056/NEJMoa1804092?url\_ver=Z39.88-2003=ori%3Arid%3Acrossref.org=cr\_pub++0www.ncbi.nlm.nih.gov](https://www.nejm.org/doi/10.1056/NEJMoa1804092?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0www.ncbi.nlm.nih.gov)

# Article summary:

1. Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, was found to be effective in reducing severe asthma exacerbations and improving lung function in patients with uncontrolled asthma.

2. The study involved 1902 patients aged 12 or older who were randomly assigned to receive either dupilumab or a placebo for 52 weeks. Patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control.

3. Greater benefits were seen in patients with higher baseline levels of eosinophils, but hypereosinophilia was observed in some patients who received dupilumab.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

作为一篇原始研究文章，该文提供了关于Dupilumab在控制不良的哮喘患者中的疗效和安全性的数据。然而，该文章存在一些偏见和缺失。

首先，该文章没有提及任何可能的负面影响或副作用。这可能会导致读者对使用Dupilumab时可能出现的风险缺乏充分认识。

其次，该文章没有探讨其他治疗选择与Dupilumab相比的优劣。这使得读者难以确定是否应该将Dupilumab作为治疗不良哮喘的首选药物。

此外，该文章没有考虑到患者个体差异对Dupilumab疗效和安全性的影响。例如，年龄、性别、种族、基线哮喘严重程度等因素都可能影响药物反应和耐受性。

最后，由于本文是由制药公司赞助进行的临床试验，因此存在潜在偏见。制药公司可能会有利益驱动来推销自己的产品，并可能会选择公布有利于其产品的结果。

综上所述，虽然该文章提供了有关Dupilumab在治疗不良哮喘方面的初步数据，但读者应该注意到其中存在的偏见和缺失，并谨慎评估其结果。

# Topics for further research:

* Potential negative effects or side effects of Dupilumab
* Comparison of Dupilumab with other treatment options
* Individual differences in patient response to Dupilumab
* Potential bias in the study due to pharmaceutical company sponsorship
* Limitations and biases in the study design
* Caution in interpreting the results of the study

# Report location:

<https://www.fullpicture.app/item/3381bd1de62501b606e1b1167894030d>